Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Artemisinin combination therapy (ACT) with artemether lumefantrine (AL) is currently the
first line treatment policy in Kenya. AL is an efficacious drug that also has the capacity to
reduce malaria transmission to mosquitoes. Nevertheless, there is concern about the
development of parasite resistance against AL. Clinical trials in Asia showed that
mefloquine-artesunate (MQ-AS) may be more efficacious than AL and may have a more pronounced
beneficial effect on post-treatment malaria transmission. MQ-AS is registered and used in
Kenya but there have been no reported direct comparisons of AL and MQ-AS with clinical and
transmission endpoints (i.e. adequately clearing parasites and preventing transmission to
mosquitoes).
Screening for molecular markers that are related to parasite susceptibility to ACT drugs and
to post-ACT treatment malaria transmission can assist strategies to prevent the development
and spread of ACT resistance.
In the current study, we compare AL and MQ-AS for the treatment of uncomplicated malaria. Our
endpoints are i) clinical efficacy, ii) post-treatment gametocytaemia by molecular
techniques.
In the current study, the investigators compare AL and MQ-AS for the treatment of
uncomplicated malaria. The investigators endpoints are
clinical efficacy post-treatment gametocytaemia by molecular techniques
Phase:
Phase 3
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborators:
European Union Kilimanjaro Christian Medical Centre, Tanzania Radboud University